Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study.

Ana Florea Lina S SyYi LuoLei QianKatia J BruxvoortBradley K AckersonGina S LeeJennifer H KuJulia E TubertYun TianCarla A TalaricoHung Fu Tseng

Published in: PloS one (2022)

These interim results provide continued evidence for protection of 2 doses of mRNA-1273 against SARS-CoV-2 infection over 8 months post-vaccination and during the Delta period, and against COVID-19 hospitalization and hospital death.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
healthcare
binding protein
emergency department
adverse drug
acute care